Intro - Slide 1 join us virtually Guardant Health at the ASCO Annual Meeting
June 4-8, 2021 • Online
Learn More
Key Abstracts Products Press Releases Contact us Overview scroll scroll

Delivering the Promise of Precision Oncology
Across the Care Continuum

 Guardant Health, along with leading academic institutions and pharmaceutical companies, will present exciting new data on its liquid biopsy technology.
Industry Experts Theater
Clinical Science Symposium
Poster Presentations

Step inside our
virtual booth!

Explore how Guardant Health is transforming cancer care through its portfolio of proprietary liquid biopsy tests, vast data sets and advanced analytics. 
Enter Now

TREAT WITH CONFIDENCE

Support copy with go here

INFORM TREATMENT DECISIONS

The insights you need to optimize therapy

ENHANCE YOUR PRACTICE

Guardant360 CDx as routine part of care

Slide 4 Actionable Insights Across the Care Continuum Guardant Health’s suite of liquid biopsy tests provide valuable insights that have a meaningful impact on patients at all stages of the disease. back next
EXPANDED PRODUCT OFFERINGS

Coming Soon

Guardant360 TissueNext™
Find patients eligible for immunotherapy and targeted therapy by adding Guardant360 TissueNext to your liquid-first biomarker testing approach. Our streamlined testing paradigm identifies more patients with actionable biomarkers—faster.
Guardant360 Response™
Get an earlier view to patients’ response to immunotherapy and targeted therapy – weeks before their first scan. Guardant360 Response measures changes in ctDNA levels to assess response to treatment.
VISIT OUR BOOTH TO LEARN MORE
VIDEO ON DEMAND

Industry Expert Theater

Optimizing mNSCLC Treatment with Guideline-Complete Liquid Biopsy

Becky Nagy, MS LGC
Vice President, Medical Affairs, Guardant Health
watch now

Key Abstracts

Findings demonstrate the value of Guardant Health’s liquid biopsy tests in detecting actionable biomarkers, informing treatment decisions, and revealing tumor evolution and resistance in response to therapy, including immunotherapies.
JUNE 4-8, ON-DEMAND VIEWING

Poster Session: Gastrointestinal Cancer—Colorectal and Anal
JUNE 4-8, ON-DEMAND VIEWING

Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Poster Session: Gastrointestinal Cancer—Colorectal and Anal

Poster Session: Gastrointestinal Cancer—Colorectal and Anal


JUNE 4-8, ON-DEMAND VIEWING

Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Clinical Science Symposium: Circulating Tumor DNA: A Versatile Analyte to Guide the Care of Patients With Lung Cancer

Poster Session: Breast Cancer—Metastatic

Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Poster Session: Genitourinary Cancer—Kidney and Bladder

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Poster Session: Gastrointestinal Cancer—Colorectal and Anal

Poster Session: Gastrointestinal Cancer—Colorectal and Anal

Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile

Poster Session: Session: Gastrointestinal Cancer—Colorectal and Anal

Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Poster Session: Gastrointestinal Cancer—Colorectal and Anal













JUNE 4-8, ON-DEMAND VIEWING 

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Transforming Cancer CareThrough Liquid Biopsy

Guardant Health’s portfolio of liquid biopsies, provide valuable insights that have a meaningful impact on patients at all stages of the disease.
Proof Point 1

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.

Proof Point 2

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.

Proof Point 3

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.

Recent News

View our latest press releases
June 4, 2021
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
MAY 28, 2021
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound
Tap outside menu to close